Sugi Predict

Sugi Predict / Compounds / SCHEMBL17858833

SCHEMBL17858833

SCHEMBL17858833

Cc1cc(C(=O)O)cc(C(F)(F)F)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.47
▸ HSP90AB1 P08238 1/20 0.47
▸ RBP4 P02753 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ TPMT P51580 1/20 0.42
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SORT1 Q99523 1/20 0.38
▸ ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12098246 0.86 ALOX15 (0.48) ALOX15TSHRHIF1ASMN1; SMN2
SCHEMBL26239368 0.85 HSP90AA1 (0.47) HSP90AA1HSP90AB1ALDH1A1POLBHSD17B10
SCHEMBL20346113 0.83 MAPT (0.44) RBP4ALDH1A1TPMTALOX15TSHR
SCHEMBL27250198 0.81 HSP90AA1 (0.43) HSP90AA1HSP90AB1ALDH1A1POLBHSD17B10
SCHEMBL1179149 0.80 TPMT (0.56) ALDH1A1HSD17B10TPMTALOX15TSHR
SCHEMBL11964240 0.79 ALOX15 (0.42) ALOX15TSHRHIF1AMAPTSMN1; SMN2
SCHEMBL17005467 0.78 ALOX15 (0.41) POLBALOX15TSHRHIF1ASMN1; SMN2
SCHEMBL3243480 0.78 TPMT (0.42) POLBTPMTALOX15TSHRHIF1A
SCHEMBL31443000 0.78 TPMT (0.42) POLBTPMTALOX15TSHRHIF1A
Hydrochloric Acid SCHEMBL11078337 0.78 TPMT (0.54) ALDH1A1HSD17B10TPMTALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
CN-109923116-B [1,2,4] triazolo [1,5-a ] pyrimidine derivatives as PDE2 inhibitors 詹森药业有限公司 2022-12-06 — — CN disclosed
EP-3962484-A1 INHIBITORS OF RAF KINASES Kinnate Biopharma Inc. (US) 2022-03-09 — — EP disclosed
CN-114072148-A Inhibitors of RAF kinase 金耐特生物制药公司 2022-02-18 — — CN disclosed
US-20210246135-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2021-08-12 — — US disclosed
US-20210246135-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2021-08-12 — — US disclosed
US-10947242-B2 [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2021-03-16 — — US disclosed
US-10927111-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2021-02-23 — — US disclosed
WO-2020227020-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2020-11-12 — — WO disclosed
WO-2020227020-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2020-11-12 — — WO disclosed
US-20200347052-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2020-11-05 — — US disclosed
US-20200347052-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2020-11-05 — — US disclosed
US-20190276462-A1 [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-09-12 — — US disclosed
EP-3535267-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS Janssen Pharmaceutica NV (BE) 2019-09-11 — — EP disclosed
CN-109923116-A [1,2,4] triazol [1,5-A] pyrimidine derivatives as PDE2 inhibitor 詹森药业有限公司 2019-06-21 — — CN disclosed
EP-3233831-B1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-02-20 — — EP disclosed
US-9938278-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2018-04-10 — — US disclosed
WO-2016096116-A1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347052-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, NRAS HSP90AA1 865/4885HSP90AB1 598/4885RBP4 3828/4885
US-20190276462-A1 [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS PDE2A, PDE12, PDE5A HSP90AA1 3324/4885HSP90AB1 3416/4885RBP4 4207/4885
US-11667634-B2 Inhibitors of RAF kinases BRAF, RAF1, NRAS HSP90AA1 865/4885HSP90AB1 598/4885RBP4 3828/4885
US-10927111-B2 Inhibitors of RAF kinases BRAF, RAF1, NRAS HSP90AA1 865/4885HSP90AB1 598/4885RBP4 3828/4885
US-20210246135-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, NRAS HSP90AA1 865/4885HSP90AB1 598/4885RBP4 3828/4885
US-10947242-B2 [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors PDE2A, PDE12, PDE5A HSP90AA1 3664/4885HSP90AB1 3748/4885RBP4 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.